Andreas BrÃ¸nden

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7785136/publications.pdf

Version: 2024-02-01

20	401	759233 12	752698 20
papers	citations	h-index	g-index

20	20	20	709
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. BMJ Open, 2021, 11, e044711.	1.9	3
2	Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials. Journal of Diabetes and Its Complications, 2020, 34, 107446.	2.3	3
3	Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 362-373.	3.6	11
4	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 871-882.	1.8	10
5	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. Clinical and Translational Gastroenterology, 2020, 11, e00257.	2.5	8
6	Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. Gastroenterology, 2019, 157, 569-571.	1.3	16
7	Glucoseâ€lowering effects and mechanisms of the bile acidâ€sequestering resin sevelamer. Diabetes, Obesity and Metabolism, 2018, 20, 1623-1631.	4.4	21
8	The bile acidâ€sequestering resin sevelamer eliminates the acute <scp>GLP</scp>â€1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 362-369.	4.4	33
9	Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes. Expert Opinion on Drug Discovery, 2018, 13, 1161-1167.	5.0	9
10	Effects of liraglutide on gallbladder emptying: A randomized, placeboâ€controlled trial in adults with overweight or obesity. Diabetes, Obesity and Metabolism, 2018, 20, 2557-2564.	4.4	28
11	Cardiovascular safety and benefits of GLP-1 receptor agonists. Expert Opinion on Drug Safety, 2017, 16, 351-363.	2.4	30
12	Exenatide: pharmacokinetics, clinical use, and future directions. Expert Opinion on Pharmacotherapy, 2017, 18, 555-571.	1.8	58
13	Shortâ€acting glucagonâ€like peptideâ€1 receptor agonists as addâ€on to insulin therapy in type 1 diabetes: <scp>A</scp> review. Diabetes, Obesity and Metabolism, 2017, 19, 915-925.	4.4	10
14	Evidence connecting old, new and neglected glucoseâ€lowering drugs to bile acidâ€induced <scp>GLP</scp>â€1 secretion: <scp>A</scp> review. Diabetes, Obesity and Metabolism, 2017, 19, 1214-1222.	4.4	14
15	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. Clinical Pharmacokinetics, 2017, 56, 719-731.	3.5	18
16	Single-Dose Metformin Enhances Bile Acidâ€“Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4153-4162.	3.6	27
17	Involvement of glucagonâ€like peptideâ€1 in the glucoseâ€lowering effect of metformin. Diabetes, Obesity and Metabolism, 2016, 18, 955-961.	4.4	50
18	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2076-2083.	3.6	24

#	Article	IF	Citations
19	The zinc transporter ZNT3 co-localizes with insulin in INS-1E pancreatic beta cells and influences cell survival, insulin secretion capacity, and ZNT8 expression. BioMetals, 2016, 29, 287-298.	4.1	15
20	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 1493-1503.	3.3	13